Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Interest & Investment Income (2022 - 2025)

Foghorn Therapeutics (FHTX) has 4 years of Interest & Investment Income data on record, last reported at $1.7 million in Q4 2025.

  • For Q4 2025, Interest & Investment Income changed N/A year-over-year to $1.7 million; the TTM value through Dec 2025 reached $10.1 million, changed N/A, while the annual FY2025 figure was $8.7 million, N/A changed from the prior year.
  • Interest & Investment Income reached $1.7 million in Q4 2025 per FHTX's latest filing, down from $2.0 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $3.5 million in Q3 2024 and bottomed at $235000.0 in Q1 2022.
  • Average Interest & Investment Income over 4 years is $2.2 million, with a median of $2.4 million recorded in 2024.
  • Peak YoY movement for Interest & Investment Income: surged 1035.74% in 2023, then crashed 41.86% in 2025.
  • A 4-year view of Interest & Investment Income shows it stood at $2.4 million in 2022, then rose by 11.95% to $2.7 million in 2023, then soared by 31.39% to $3.5 million in 2024, then plummeted by 51.02% to $1.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $1.7 million in Q4 2025, $2.0 million in Q3 2025, and $3.5 million in Q3 2024.